Meihua Medical Technologies Files 6-K on Nasdaq Status
Ticker: MHUAF · Form: 6-K · Filed: Oct 7, 2024 · CIK: 1835615
| Field | Detail |
|---|---|
| Company | Meihua International Medical Technologies Co., Ltd. (MHUAF) |
| Form Type | 6-K |
| Filed Date | Oct 7, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: listing-compliance, sec-filing, foreign-private-issuer
Related Tickers: MHUA
TL;DR
Meihua Medical Technologies (MHUA) filed a 6-K updating its Nasdaq listing status after receiving a deficiency notice.
AI Summary
Meihua International Medical Technologies Co., Ltd. (the "Company") filed a Form 6-K on October 7, 2024, to report on its status with Nasdaq. As previously disclosed on April 2, 2024, the Company received written notice from Nasdaq's Listing Qualifications Department regarding a deficiency.
Why It Matters
This filing provides an update on the company's compliance status with Nasdaq listing requirements, which could impact its stock trading and investor confidence.
Risk Assessment
Risk Level: medium — The filing indicates a potential issue with Nasdaq listing requirements, which could lead to delisting if not resolved.
Key Players & Entities
- Meihua International Medical Technologies Co., Ltd. (company) — Registrant
- Nasdaq Stock Market LLC (company) — Listing Exchange
- April 2, 2024 (date) — Date of initial notice
- 001-41291 (other) — SEC File Number
FAQ
What was the specific reason for the deficiency notice from Nasdaq?
The provided text states that the Company received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC regarding a deficiency, but the specific reason is not detailed in this excerpt.
When did the Company first receive the deficiency notice from Nasdaq?
The Company first received the written notice from Nasdaq on April 2, 2024.
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the company may be required to disclose to its home country security holders.
Does the company file annual reports under Form 20-F or 40-F?
The company indicates it files annual reports under cover of Form 20-F.
What is the principal executive office address of Meihua International Medical Technologies Co., Ltd.?
The principal executive office is located at 88 Tongda Road, Touqiao Town, Guangling District, Yangzhou, 225000, People's Republic of China.
Filing Stats: 335 words · 1 min read · ~1 pages · Grade level 11.6 · Accepted 2024-10-07 06:04:09
Key Financial Figures
- $1.00 — any’s ordinary shares has been at $1.00 per share or greater. On October 3, 202
Filing Documents
- ea0216908-6k_meihua.htm (6-K) — 11KB
- ea021690801ex99-1_meihua.htm (EX-99.1) — 6KB
- 0001213900-24-085693.txt ( ) — 18KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Meihua International Medical Technologies Co., Ltd. Dated: October 7, 2024 By: /s/ Xin Wang Name: Xin Wang Title: Chief Executive Officer (Principal Executive Officer) 2